Barinthus Biotherapeutics has reshaped its clinical focus around its proprietary SNAP-TI platform, principally advancing VTP-1000 for celiac disease after a substantial restructuring that cut workforce and closed UK operations. Financially, the company continues to burn cash with operating losses edging worse by mid-single digits year-over-year, though cost cuts reduced capital expenditures sharply. The pending merger with Clywedog in 2026 promises pipeline diversification but introduces execution risk. Investors should monitor upcoming Phase 1 data readouts for VTP-1000, partnership moves on the legacy hepatitis B candidate, and progress toward merger closure.